Section Arrow
TBPH.NASDAQ
- Theravance Biopharma
Quotes are at least 15-min delayed:2025/07/20 18:31 EDT
Regular Hours
Last
 11.25
-0.37 (-3.18%)
Day High 
11.69 
Prev. Close
11.62 
1-M High
11.88 
Volume 
144.45K 
Bid
11.22
Ask
11.26
Day Low
11.235 
Open
11.68 
1-M Low
10.435 
Market Cap 
581.02M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.43 
20-SMA 11.12 
50-SMA 10.4 
52-W High 11.88 
52-W Low 7.44 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.18/-0.33
Enterprise Value
620.12M
Balance Sheet
Book Value Per Share
3.32
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
64.38M
Operating Revenue Per Share
1.03
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 18:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.